Skip to main content
    S

    Summit Therapeutics PLC (SMMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.82
    -2.33 (-16.47%)

    Market Cap: $11.32B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Summit Therapeutics PLC (SMMT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Summit Therapeutics are TG Therapeutics (TGTX), Spyre Therapeutics (SYRE) and Protagonist Therapeutics (PTGX). By market cap, Summit Therapeutics ranks 5th of the 13 companies on this page; Exelixis (EXEL) is the largest at $16.84B. The median P/E of the 5 companies with a P/E is 27.7x.

    Peer Comparison

    SMMT's revenue growth of -100.0% is below the peer median of 45.5%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Summit Therapeutics (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Bio-Techne Corp (TECH)$11.44B39.6x9.3x14.0%7.7%4.6%0.44%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Axsome Therapeutics Inc (AXSM)$7.45BN/A8.6x-18.2%-48.1%51.9%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Kymera Therapeutics Inc (KYMR)$10.89BN/A123.2x0.0%N/A466.4%0.00%
    Twist Bioscience Corp (TWST)$7.40BN/A14.3x-28.3%N/A27.9%0.00%
    Peer median$10.05B27.7x11.1x0.0%7.7%45.5%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Summit Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Bio-Techne Corp (TECH)
    Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments...
    TECH competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Axsome Therapeutics Inc (AXSM)
    Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United...
    AXSM competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors
    Kymera Therapeutics Inc (KYMR)
    Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down...
    KYMR competitors
    Twist Bioscience Corp (TWST)
    Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.
    TWST competitors

    Frequently Asked Questions About SMMT

    Who are Summit Therapeutics' main competitors?

    The companies most similar to Summit Therapeutics include TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), Protagonist Therapeutics (PTGX), Bio-Techne (TECH) and Apogee Therapeutics, Inc. Common Stock (APGE), listed from the closest match.

    Who is Summit Therapeutics' biggest competitor?

    Exelixis (EXEL) is the largest of the similar companies at $16.84B; TG Therapeutics (TGTX) is the closest match by business profile, size, sector and industry.

    How does SMMT stock compare with its competitors?

    SMMT's net margin is 0.0% against a peer median of 0.0%.

    Which of Summit Therapeutics' competitors pays a higher dividend?

    Summit Therapeutics pays no dividend. Bio-Techne (TECH) has a higher forward dividend yield; Bio-Techne (TECH) has the highest at 0.44%.

    Is Summit Therapeutics bigger than its competitors?

    No. Summit Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Exelixis (EXEL) at $16.84B.